On November 6, 2024, Carl Dambkowski, the Chief Medical Officer of Apogee Therapeutics Inc (APGE, Financial), executed a sale of 6,665 shares of the company. The transaction was filed with the SEC and can be viewed in detail through the SEC Filing. Following this transaction, the insider now owns 267,463 shares of Apogee Therapeutics Inc.
Apogee Therapeutics Inc is engaged in the development of therapies aimed at treating autoimmune and inflammatory diseases. The company's focus on innovation and development in these healthcare sectors positions it as a notable player in the biopharmaceutical industry.
Over the past year, Carl Dambkowski has sold a total of 33,325 shares and has not made any purchases of the stock. This recent sale is part of a broader trend observed within the company, where there have been 11 insider sells and no insider buys over the past year.
Shares of Apogee Therapeutics Inc were priced at $59.12 on the day of the transaction. The company's market cap is approximately $3.46 billion. This valuation reflects the company's standing and investor expectations in the market.
For further insights into the company's valuation metrics such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors can visit the respective links.
This insider sale might be of interest to current and potential investors trying to understand market trends and the actions of key executives within Apogee Therapeutics Inc.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
